Ex­clu­sive: Cell and gene ther­a­py CD­MO VintaBio emerges on­to the scene with $64M and a new CEO

A con­tract man­u­fac­tur­er is emerg­ing from stealth with cash on hand and a new CEO — and jump­ing right in­to the busy cell and gene ther­a­py pro­duc­tion space.

On Tues­day, VintaBio an­nounced that it has raised $64 mil­lion in a fund­ing round and has brought in David Rad­spin­ner to lead the out­fit as CEO. VintaBio is a Philadel­phia-based CD­MO serv­ing the cell and gene ther­a­py mar­ket. It was start­ed around three years ago by Jun­wei Sun and Shangzhen Zhou, who helped de­vel­op the first vi­ral vec­tors used in the first CAR-T to treat can­cer as well as ear­ly gene ther­a­pies while at the Uni­ver­si­ty of Penn­syl­va­nia.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN